WallStreetZenWallStreetZen

NASDAQ: AVTX
Avalo Therapeutics Inc Earnings & Revenue

AVTX past revenue growth

How has AVTX's revenue growth performed historically?
Company
-87.05%
Industry
165.61%
Market
17.84%
AVTX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
AVTX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
AVTX's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

AVTX earnings and revenue history

Current Revenue
$2.3M
Current Earnings
-$33.2M
Current Profit Margin
-1,475%

AVTX Return on Equity

Current Company
N/A
Current Industry
15.4%
Current Market
-8.4%

Be the first to know when AVTX announces earnings.

AVTX Return on Assets

Current Company
-107.8%
Current Industry
2.2%
AVTX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

AVTX Return on Capital Employed

Current Company
-123.4%
Current Industry
17.7%
AVTX's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

AVTX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
AVTX$2.25M-$28.56M-$33.19M-32.09%N/A
SNTI$2.56M-$65.63M-$71.06M+152.19%N/A
NERV$0.00-$29.97M-$30.01M-100.00%N/A
PIRS$47.36M-$25.47M-$28.06M+2.26%N/A
KPRX$0.00-$12.35M-$13.04M-100.00%N/A

AVTX earnings dates

Next earnings date
May 2, 2024

Avalo Therapeutics Earnings & Revenue FAQ

What were AVTX's earnings last quarter?

On Invalid Date, Avalo Therapeutics (NASDAQ: AVTX) reported Q3 2023 earnings per share (EPS) of -$26.40, up 132.35% year over year. Total Avalo Therapeutics earnings for the quarter were -$5.23 million. In the same quarter last year, Avalo Therapeutics's earnings per share (EPS) was $81.60.

If you're new to stock investing, here's how to buy Avalo Therapeutics stock.

What was AVTX's earnings growth in the past year?

As of Q1 2024, Avalo Therapeutics's earnings has grown year over year. Avalo Therapeutics's earnings in the past year totalled -$33.19 million.

What is AVTX's earnings date?

Avalo Therapeutics's earnings date is Invalid Date. Add AVTX to your watchlist to be reminded of AVTX's next earnings announcement.

What was AVTX's revenue last quarter?

On Invalid Date, Avalo Therapeutics (NASDAQ: AVTX) reported Q3 2023 revenue of $236.00 thousand up 98.42% year over year. In the same quarter last year, Avalo Therapeutics's revenue was $14.95 million.

What was AVTX's revenue growth in the past year?

As of Q1 2024, Avalo Therapeutics's revenue has grown -87.05% year over year. This is 252.66 percentage points lower than the US Biotechnology industry revenue growth rate of 165.61%. Avalo Therapeutics's revenue in the past year totalled $2.25 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.